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Abstract
The CABLES1 cell cycle regulator participates in the adrenal–pituitary negative feedback, 
and its expression is reduced in corticotropinomas, pituitary tumors with a largely 
unexplained genetic basis. We investigated the presence of CABLES1 mutations/copy 
number variations (CNVs) and their associated clinical, histopathological and molecular 
features in patients with Cushing’s disease (CD). Samples from 146 pediatric (118 
germline DNA only/28 germline and tumor DNA) and 35 adult (tumor DNA) CD patients 
were screened for CABLES1 mutations. CNVs were assessed in 116 pediatric CD patients 
(87 germline DNA only/29 germline and tumor DNA). Four potentially pathogenic 
missense variants in CABLES1 were identified, two in young adults (c.532G > A, p.E178K 
and c.718C > T, p.L240F) and two in children (c.935G > A, p.G312D and c.1388A > G, and 
p.D463G) with CD; no CNVs were found. The four variants affected residues within or 
close to the predicted cyclin-dependent kinase-3 (CDK3)-binding region of the CABLES1 
protein and impaired its ability to block cell growth in a mouse corticotropinoma cell 
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line (AtT20/D16v-F2). The four patients had macroadenomas. We provide evidence for 
a role of CABLES1 as a novel pituitary tumor-predisposing gene. Its function might 
link two of the main molecular mechanisms altered in corticotropinomas: the cyclin-
dependent kinase/cyclin group of cell cycle regulators and the epidermal growth factor 
receptor signaling pathway. Further studies are needed to assess the prevalence of 
CABLES1 mutations among patients with other types of pituitary adenomas and to 
elucidate the pituitary-specific functions of this gene.
Introduction
In recent years, germline defects in multiple genes have 
been linked to the pathogenesis of pituitary adenomas, 
both with syndromic and isolated presentation (Caimari & 
Korbonits 2016). In contrast with other types of pituitary 
tumors, corticotropinomas are infrequent in patients with 
‘classic’ multiple endocrine neoplasia and have rarely 
been described in the setting of familial isolated pituitary 
adenoma (FIPA) (Stratakis et al. 2010, Cazabat et al. 2012). 
Consequently, the germline abnormalities leading to 
corticotroph cell tumorigenesis remain largely unknown. 
On the other hand, somatic mutations in the USP8 gene 
hotspot are highly prevalent among corticotropinomas 
in adult and pediatric patients, but they have not been 
detected in other types of pituitary adenomas (Pérez-
Rivas et al. 2015, Reincke et al. 2015). Therefore, it might 
be that the majority of the corticotropinomas are caused 
by disruptions in molecular pathways that are not shared 
by other pituitary tumor types.
The CABLES1 (Cdk5 and ABL enzyme substrate 
1) gene (18q11.2) is a negative regulator of cell cycle 
progression that is activated in corticotroph cells in 
response to glucocorticoids (Roussel-Gervais  et  al. 
2016). The physiological negative feedback exerted by 
glucocorticoids on the corticotroph cells is often impaired 
in corticotropinomas, and, concordantly, CABLES1 
protein expression is lost in around half of such tumors 
(Roussel-Gervais et al. 2010, Roussel-Gervais et al. 2016). 
CABLES1 gene inactivation by allelic loss, aberrant splicing 
or promoter hypermethylation has been observed in 
different types of human cancers but, to our knowledge, 
it has not been explored in pituitary adenomas before 
(Tan et al. 2003, Zhang et al. 2005, Sakamoto et al. 2008). 
Moreover, there are no human phenotypes reported in 
association with CABLES1 germline mutations (http://
omim.org/entry/609194, accessed: 28-03-17). Therefore, 
we investigated the presence of CABLES1 gene mutations 
and copy number variations (CNV) in a large group of 
patients with Cushing’s disease (CD).
Materials and methods
Pediatric Cushing’s disease cohort
We studied 146 pediatric (<18 years at diagnosis) patients 
with CD who are part of a large cohort evaluated at the 
outpatient clinic and/or admitted for clinical work-up 
and treatment at the National Institutes of Health (NIH) 
Clinical Center between 1997 and 2017 and recruited 
under the research protocol 97-CH-0076 (ClinicalTrials.
gov: NCT00001595). The Eunice Kennedy Shriver National 
Institute of Child Health and Human Development 
Institutional Review Board approved this study, and 
informed assent/consent was obtained from all the 
patients and their parents/guardians. Clinical data were 
obtained directly from the patients and/or from the 
Clinical Research Information System. Parents and siblings 
of the patients were also recruited, when available.
For all the individuals, DNA was extracted either from 
a peripheral blood sample using the Maxwell 16 Blood 
DNA Purification Kit in a Maxwell 16 Instrument (Promega 
AS1015 and AS3050) or from saliva using the Oragene-Dx 
collection kit and the PrepIT-L2P DNA extraction kit 
(DNA Genotek OGD-500 and PT-L2P-45), according to 
the manufacturer’s protocols. When available, stained 
histopathological sections from the corticotropinomas 
were retrieved from the Department of Pathology. 
After either manual delimitation of the tumor area or 
microdissection, DNA was extracted from unstained 
sections using the Pinpoint Slide DNA Isolation System 
(Zymo Research D3001). Screening for germline mutations 
in AIP, CDKN1B, CDKN2C, MEN1, and PRKAR1A in 74 
of these patients, and GPR101 in 34 of them, as well as 
somatic GPR101 defects in 23 corticotropinoma DNA 
samples from these patients has been reported before 
(Stratakis et al. 2010, Trivellin et al. 2016).
Germline DNA samples from 98 patients and tumor 
DNA samples from 28 of them were submitted for 
whole-exome sequencing (WES) at the University of 
Minnesota Genomics Center. Targeted capture libraries 
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were generated using the Agilent QXT v5 + UTRs kit 
for both germline and tumor samples. The germline 
samples were sequenced on an Illumina HiSeq 2000 
platform producing 100 bp paired-end reads, while 
the tumor samples were sequenced on a HiSeq 2500 
platform producing 125 bp paired-end reads. FASTQ 
files were processed using the steps delineated in the 
Broad Institute’s Genome Analysis Toolkit (GATK) best 
practices (Van der Auwera  et  al. 2013), including using 
BWA-MEM (Li & Durbin 2010) for alignment, GATK for 
quality recalibration and indel realignment and GATK 
HaplotypeCaller for genotyping. The median number 
of on-target reads generated per sample was 41 million, 
resulting in median target coverage of 54× (78% of targets 
covered at >20×). For CABLES1, the median percent of the 
10 coding exons covered at 20× was 100% (average = 91%). 
The only exon with reduced coverage was exon 1, 
with 43% of samples having 20× coverage. ANNOVAR 
(Wang  et al. 2010a) was used to determine the effect of 
coding variants using both the RefSeq and UCSC gene 
sets, including putative amino acid changes, distance 
to intron–exon boundary, the creation or removal of a 
stop-codon and location within known non-coding 
RNAs. Nonsynonymous variants were annotated based 
on their computationally predicted deleteriousness using 
information from dbNSFP. All variants were annotated 
for their frequency and presence in multiple variant 
collections (e.g., dbSNP, 1000 Genomes and internal 
WES datasets totaling over 10,000 samples). Targeted 
bioinformatic analysis ruled out rare mutations (present 
in <1% of any variant collection) in other known pituitary 
adenoma-associated genes (AIP, CDKN1B, GPR101, MEN1 
and PRKAR1A). For all the samples, a manual check of 
the WES raw data for CABLES1 was performed, using 
the Integrative Genomics Viewer 2.3.72 platform (Broad 
Institute) (Robinson et al. 2011).
In addition, 48 other patients were screened for 
germline CABLES1 variants by Sanger sequencing. The 
primers included in Supplementary Table  1 (see section 
on supplementary data given at the end of this article) 
were used to amplify the coding regions and exon–intron 
junctions by PCR (GoTaq Green Master Mix, Promega 
M7123) and for Sanger sequencing (BigDye Terminator 3.1 
Cycle Sequencing Kit, Thermo Fisher Scientific 4337456). 
Sequences were analyzed using the SeqMan Pro 11.1.0 
(DNASTAR) software. The Alamut Visual 2.9 software 
(Interactive Biosoftware) was used for the annotation, 
in silico prediction and to search the frequency in public 
databases of all the variants identified. Four algorithms 
(Align GVGD, PolyPhen-2, SIFT and Mutation Taster) 
were used for missense variants and five (Splice Site 
Finder, MaxEnt, NNSplice, GeneSplicer and Human Site 
Finder) were used for splicing variants. Variants were 
considered probably damaging or affecting splicing when 
the majority of the algorithms agreed; otherwise, they 
were considered variants of uncertain significance (VUS). 
Sanger sequencing confirmed all the variants identified 
by WES. Parents of the patients with CABLES1 variants of 
interest were screened ad hoc, and loss of heterozygosity 
(LOH) was investigated in the corticotropinomas by 
Sanger sequencing.
Collection of corticotropinomas from adult patients
Fresh frozen corticotropinoma tissue samples were 
obtained from 35 adult patients from Cochin Hospital 
and Foch Hospital operated for CD between 2009 and 
2016. The local ethical committee approved the study, 
and all the patients provided written informed consent. 
RNA was extracted using the RNeasy kit (QIAGEN), and 
then reverse-transcribed. All the samples were submitted 
for RNA sequencing (RNA-seq) at the genomic platform 
of Cochin Institute. The libraries were prepared following 
the TruSeq mRNA protocol (Illumina RS-122-2101), 
starting from 1 μg of high-quality total RNA. Paired-end 
(2 × 75 bp) sequencing was performed in an Illumina 
NextSeq 500 instrument. Reads were aligned using the 
STAR software (Dobin & Gingeras 2015). Sequencing 
variants were annotated using ANNOVAR (Wang  et  al. 
2010a) and then filtered for exonic nonsynonymous 
variants, with frequency <1% in the general population 
(based on the 1000 Genomes database) (1000 Genomes 
Project Consortium et al. 2015). Variants of interest were 
confirmed by Sanger sequencing in DNA extracted from 
representative sections of paraffin-embedded tissues, as 
described previously.
Copy number variation analysis
CNV analysis was performed in 116 germline and 29 
corticotropinoma DNA samples using FAM-labeled assays 
binding CABLES1 exon 1, intron 3–exon 4 and exon 10 
(TaqMan CNV assays Hs07536236_cn, Hs02003953_cn, 
and Hs00413958_cn, respectively, Thermo Fisher 
Scientific) a VIC-labeled RPP30 (Rnase P) assay (Thermo 
Fisher Scientific 4403326) as an internal control, and the 
ddPCR SuperMix for Probes (no dUTP) (Bio-Rad 1863024) 
in a QX200 Droplet Digital PCR System (Bio-Rad). Results 
were analyzed with the Quanta Soft software 1.7.4.0917 
(Bio-Rad).
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USP8 screening
For patients with potentially pathogenic CABLES1 
variants, the primers 5′-CTTCCACCCCTCCAACTCAT-3′ 
and 5′-TGGAGTTACTGTTGGCTTCCT-3′ were used to 
amplify and sequence a region of 146 bp covering the 
USP8 mutational hotspot in corticotropinoma DNA, as 
described above. Patients with USP8 mutations from our 
cohort have been reported elsewhere (Pérez-Rivas  et  al. 
2015, Faucz et al. 2017).
Immunohistochemistry
In corticotropinomas from patients with putative 
CABLES1 mutations and in two corticotropinomas 
with no mutations, immunohistochemical staining for 
ACTH (1:1000 rabbit polyclonal anti-ACTH antibody, 
Abcam 74976), CABLES1 (1:1000 rabbit polyclonal 
Abcam ab75535) and CDKN1B (1:100 rabbit polyclonal 
Santa Cruz sc-528) was performed as follows: 
deparaffinization for 30 min in Histo-Clear (National 
Diagnostics HS-200), sequential 5-min washes with 100, 
95, 70 and 50% ethanol, antigen retrieval with citrate-
based antigen unmasking solution (Vector H3300) for 
20 min in a steamer, blocking for 1 h with 10% normal 
goat serum (Jackson ImmunoResearch Laboratories 
005-000-121) in 1× PBS/0.1% Triton X-100, incubation 
with primary antibody overnight at 4°C, incubation 
with 1% H2O2 for 5 min, and then for 1 h with 1:1000 
Biotin-SP AffiniPure Goat Anti-rabbit IgG and for 
30 min with 1:500 Peroxidase Streptavidin (Jackson 
ImmunoResearch Laboratories 111-065-144 and 016-
030-084, respectively). Samples were developed by 
incubation for 1 min with ImmPACT DAB peroxidase 
(HRP) substrate (Vector SK-4105) and counterstained 
with Gill’s hematoxylin I (American  MasterTech 
Scientific HXGHE1PT) and Dako Bluing Buffer (Agilent 
Technologies CS70230-2). Sequential washes in a 
50–100% ethanol gradient and Histo-Clear were done 
before mounting with Cytoseal XYL (Thermo Fisher 
Scientific 8312-4). Images were acquired using a Leica 
DMRX optical microscope, attached to an Olympus 
DP72 camera, and processed with the CellSens 
Dimension 1.6 software (Olympus).
Expression plasmids
The mouse Cables1 cDNA (variant 1: NM_001146287.1) 
was obtained from IDT and inserted downstream of the Ta
b
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tamoxifen-inducible form of the estrogen receptor (ERtam) 
ligand-binding domain into a 3xFlag-tagged retroviral 
expression vector derived from pLNCX2 (Littlewood et al. 
1995). Mutagenic primers were used to introduce the Cables1 
point mutations p.E139K (p.E178K in human, 5′-GCCAC-
GAGTCCTCGGGAAACCCTCACAACCAC-3′ and 
5′-GTGGTTGTGAGGGTTTCCCGAGGACTCGTGGC-3′), 
p.L201F (p.L240F in human, 5′-GGGTCAAGGGG-
TAGATTTAATTCCTTTACTCAGGG-3′ and 5′- CCCT-
GAGTAAAGGAATTAAATCTACCCCTTGACCC-3 ′) , 
p.G273D (p.G312D in human, 5′-GTCGAACACTTTCA-
GATTCTCCTAGACCAAAG-3′ and 5′-CTTTGGTC-
TAGGAGAATCTGAAAGTGTTCGAC-3′) and p.D424G 
(p.D463G in human, 5′-GACCCAAACCTCCTGGGT-
GACCCCCAGTGGCC-3′ and 5′-GGCCACTGGGGGT-
CACCCAGGAGGTTTGGGTC-3′) in the plasmid, using 
the QuikChange site-directed mutagenesis kit (Agilent 
Technologies 200519) and the KOD hotstart DNA poly-
merase (Millipore 71086). The vectors were transfected 
into EcoPackTM 2-293 cells (Clontech 631506) to produce 
the viruses, which were then used to transduce AtT-20/
D16v-F2 cells (ATCC CRL-1795).
Cell culture, transfections and growth curves
The transformed AtT-20/D16v-F2 cells were grown in 
Dulbecco’s modified Eagle medium, supplemented with 
10% fetal bovine serum and antibiotics. Pools of at least 
1 × 103 stable cell colonies were obtained as described 
(Rambaud  et al. 2009) for pLNCX2-3xFlag-ERtam-Cables1 
WT, pLNCX2-3xFlag-ERtam-Cables1 p.E178K, pLNCX2-
3xFlag-ERtam-Cables1 p.L240F, pLNCX2-3xFlag-ERtam-
Cables1 p.G312D, pLNCX2-Flag-ERtam-Cables1 p.D463G 
or pLNCX2-3xFlag-ERtam empty vector as control. Cables1 
protein levels were assessed by Western blot using 1 µg 
mouse monoclonal anti-Flag (SIGMA F1804) antibody. For 
growth curves, 7 × 105 cells per well were plated in 6-well 
plates and treated in duplicate with 400 nM tamoxifen 
(SIGMA T5648), 10−7 M dexamethasone (SIGMA D4902), 
both or vehicle (100% ethanol). Viable cells were counted 
every 12–18 h for 4  days, starting 4 h after plating, and 
medium was replaced with fresh medium at every 
time point.
Statistical analyses
All the analyses were carried out using the GraphPad 
Prism 7.0 software (GraphPad Software). Parametric data 
are presented as mean ± standard deviation (s.d.) and non-
parametric data are presented as median ± interquartile 
range (IQR). Gene variant frequencies in the study 
population were compared with the frequencies reported 
in public databases using the Fisher’s exact test. For the 
cell growth experiment with WT CABLES1, cell counts 
at each time point were compared among experimental 
conditions using one-way ANOVA with Dunnett 
correction for multiple comparisons. For the rest of the 
experiments, cell counts at different time points were 
compared between ethanol and tamoxifen treatments 
using multiple t tests, with Holm–Sidak correction for 
multiple comparisons. Results were considered statistically 
significant when P < 0.05.
Results
Genetic findings
The pediatric CD cohort was composed of 72 males and 74 
females, with mean age at first symptoms of 10.3 ± 3.3 years 
and age at diagnosis of 12.5 ± 3.4 years, for a median delay 
between disease onset and diagnosis of 26 months (IQR 
12–38.3). The median pituitary tumor size was 4 mm (IQR 
4–7); 88.1% (126/146) of the patients had microadenomas 
and 8.2% (12/146) had macroadenomas. Four patients 
(2.7%) had two or more adenomas and in four cases, the 
tumor was not identified, despite response to surgical 
treatment in three of them. The first line of treatment 
was transsphenoidal surgery in all the cases, except for 
one patient who developed spontaneous apoplexy of the 
pituitary adenoma. Ninety-seven percent of the patients 
(141/146) had sporadic presentation; among them, we 
identified two simplex patients with mutations in AIP 
and PRKAR1A, as previously reported (Stratakis et al. 2010, 
Hernández-Ramírez  et al. 2017). Out of the five familial 
cases, three were members of families with a multiple 
endocrine neoplasia phenotype (two of them with 
MEN1 mutations) as previously described (Stratakis et al. 
2010) and two had a FIPA phenotype (family history of 
prolactinomas), but tested negative for AIP mutations. 
None of the patients had a family history of CD.
The adult cohort consisted of 35 CD patients, 
including 25 females and 10 males. Mean age at diagnosis 
was 44 years (range: 16–83). A microadenoma was found 
in 22.9% (8/35) and a macroadenoma in 77.1% (27/35) of 
the patients. Seventeen patients (48.6%) presented with 
overt CD, whereas clinical signs were limited or absent for 
the rest of them.
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Four missense CABLES1 single-nucleotide variants 
of interest (each in one patient) were identified among 
the 182 patients studied (Table  1), affecting exon 1 
(c.532G > A, p.E178K and c.718C > T, p.L240F), exon 3 
(c.935G > A, p.G312D) and exon 7 (c.1388A > G, p.D463G), 
respectively (Fig. 1 and Table 1). These missense variants 
were selected because of being either novel (p.D463G) 
or very infrequent in the general population (p.E178K, 
p.G312D) and/or because they were predicted to affect 
the protein structure (p.L240F, p.D463G). The ExAC 
database reported a frequency of 2.8% for the p.E178K 
variant: this might be an overestimation, since coverage 
for CABLES1 exon 1 was low in the ExAC and gnomAD 
databases (Lek  et  al. 2016), while the 1000 Genomes 
database reported a much lower frequency. No pathogenic 
associations were reported for these variants in ClinVar or 
The Human Gene Mutation Database (Stenson et al. 2003, 
Landrum et al. 2016).
In addition, other CABLES1 variants (five of them not 
previously reported in public databases) were identified 
Figure 1
Missense CABLES1 variants of interest: effects on CABLES1 transcripts and proteins. (A) Three transcripts of CABLES1, NM_001100619.2, NM_138375.2 
and NM_001256438.1, which differ in their first exon, are translated into proteins of 633, 368 and 306 amino acids, respectively. The former 
(NM_001100619.2,) is the ‘canonical’ sequence (UniProt Q8TDN4-1). For each transcript, mRNA is schematized in blue and the coding sequence in green. 
The CABLES1 variants identified in Patients 1 and 2 (p.E178K and p.L240F), respectively, affect exon 1 of the reference transcript, but not the other 
transcripts. The variant detected in Patient 3 is located in exon 3 (p.G312D) and the variant from Patient 4 (p.D463G) affects exon 7. There is no 
information in the literature about the expression of these transcripts in the pituitary gland. (B) The domains of the CABLES1 protein are incompletely 
characterized and no 3-D structure is available that represents the majority of the protein sequence. The 633 amino acid (65.7 kDa) isoform of the 
protein contains an N-terminal site for interaction with TDRD7 and a central large sequence necessary for interacting with CDK3. Four residues are 
targets for phosphorylation: S168, S287, S313 and T415 (Shi et al. 2015, Uniprot Consortium 2015, Yamochi et al. 2001). The C-terminal end of the 
protein contains a cyclin-like domain, and for this reason, CABLES1 has been included in the cyclin superfamily, although it differs in functions with 
cyclins. The alterations found in Patients 1–4 are included in (p.L240F, p.G312D, p.D463G) or very close to (p.E178K) the motif that interacts with CDK3. 
(C) The CABLES1 gene is highly conserved among species, and the variants found in our patients affect relatively (p.E178K, p.L240F) and highly  
(p.G312D, p.D463G) conserved residues.
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in the pediatric cohort (Supplementary Table  2). Given 
the methods used for screening, we could not accurately 
assess the frequency of intronic variants. No CNVs were 
found in the samples analyzed by ddPCR.
Clinical, genetic and histopathological features in 
patients with putative CABLES1 mutations
We identified putative CABLES1 mutations in four 
sporadic female patients: two young adults (Table 2, cases 
1 and 2) and two pediatric cases (cases 3 and 4). All these 
putative mutations were found in the heterozygous state 
in the germline DNA samples, and no LOH was detected 
in the pituitary adenomas. The four tumor samples 
were negative for USP8 hotspot mutations. All these 
patients had large corticotropinomas (3/4 with extrasellar 
extension) with high Ki-67 proliferation index, and three 
of them required a second transsphenoidal surgery (and 
radiotherapy in one case) to achieve disease control.
Patient 1 presented at age 27 years with clinical 
manifestations due to the mass effect of her tumor 
(macroadenoma extending to the sphenoid and cavernous 
sinuses). She was diagnosed with a clinically non-
functioning pituitary adenoma and two transsphenoidal 
surgeries followed by radiotherapy, were required to 
achieve control. Histopathological analysis established 
the diagnosis of a silent corticotroph adenoma, with 
microscopic invasion of the dura mater, bone and 
respiratory mucosa, Ki-67 index of 6% and 2 mitoses per 
10 high-power fields.
Patient 2 presented with a clinical phenotype 
consistent with hypercortisolemia and was diagnosed 
with CD at age 32 years. Her pituitary macroadenoma 
with parasellar extension to the cavernous sinus was 
surgically removed. The resected tumor had a Ki-67 
index of 8% and 7 mitoses per 10 high-power fields, but 
invasion of surrounding structures could not be assessed 
in the specimen. Since the patient was lost to follow-up, 
we have no data of her current status.
Patient 3 was diagnosed with CD at age 16 years, after 
a one-year history of hypertension, Cushingoid features 
and weight gain (weight: 131.4 kg, height: 160 cm, BMI: 
51.3 kg/m2). She had elevated midnight cortisol (24.6 μg/
dL), and urinary free cortisol (UFC, 437 μg/dL, ×11 
ULN), unsuppressed serum cortisol (20.6 μg/dL) after 
a low-dose dexamethasone suppression test (LDDST) 
and her ACTH doubled during a CRH stimulation test 
(55.3–113 pg/mL). Her macroadenoma with suprasellar 
extension was resected, but a 15-month remission period 
was followed by recurrence, requiring a second surgery Ta
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and remaining hypercortisolemic afterward. Genetic 
screening identified paternal inheritance of her putative 
CABLES1 mutation, but despite being a carrier, her father 
was apparently unaffected.
Patient 4 had a congenital polycystic non-functional 
kidney, and her family history included one case of 
gastric cancer. She was evaluated at age 10 2/12  years 
because of decreased growth velocity (height 132 cm, −1 
s.d.), hypertension, hirsutism and Cushingoid features, 
which developed in the previous 26  months. She had 
elevated ACTH (19.1 pg/mL) and midnight cortisol (19 μg/
dL), failed a LDDST (cortisol 17 μg/dL) and had central 
hypothyroidism and dyslipidemia. Bilateral petrosal sinus 
sampling under CRH stimulation resulted in 3:1 central 
to peripheral ACTH ratio, confirming CD. Her pituitary 
adenoma without extrasellar extension was successfully 
resected, and the patient achieved remission. The 
CABLES1 alteration found in the patient was absent in 
her mother’s DNA. As a sample from the father was not 
available, we cannot determine whether the variant was 
inherited or appeared de novo.
Compared with samples without CABLES1 alterations, 
samples from Patients 1 to 4 displayed reduced CDKN1B 
cytoplasmic and, more importantly, nuclear expression 
by immunohistochemistry (Fig.  2). No differences were 
found in the CABLES1 staining between samples with and 
without putative CABLES1 mutations, although it was 
weaker in the tumors than in areas of non-tumoral pituitary 
(data not shown). This finding was not unexpected, 
as none of the samples displayed LOH for the variants 
identified, and points toward an alternative mechanism 
for reduced CABLES1 activity in the corticotroph cells.
Functional assessment of putative CABLES1 mutations
The conditional tamoxifen-inducible chimeric ERtam-
CABLES1 proteins inserted by retroviral transduction 
were expressed at similar levels among the different AtT-
20/D16v-F2 cell pools (Fig.  3A). As expected (Roussel-
Gervais et al. 2016), WT CABLES1 inhibited the growth of 
AtT-20/D16v-F2 cells, but not as much as treatment with 
the synthetic glucocorticoid dexamethasone (10−7 M) or 
their combination (Fig.  3B). This result was expected, 
as AtT-20/D16v-F2 cells express CABLES1 in response to 
dexamethasone, but CABLES1 is only one of a group of 
dexamethasone-controlled cell cycle regulators (Roussel-
Gervais  et  al. 2016). In contrast, p.E178K (Fig.  3C), 
p.L240F (Fig.  3D), p.G312D (Fig.  3E) and p.D463G 
(Fig.  3F) CABLES1 mutants lost the ability to inhibit 
AtT-20/D16v-F2 cell growth. In summary, all the CABLES1 
variants identified in our patients affect a core property 
of CABLES1: its ability to inhibit cell growth in response 
to glucocorticoids.
Discussion
The CABLES1 gene has been recently identified as a key 
mediator of the regulatory feedback loop of glucocorticoids 
on the corticotroph cells (Roussel-Gervais et al. 2016). We 
have identified a small, but not negligible number (2.2%, 
4/181) of patients with CABLES1 alterations. The four 
putative mutations identified in our patients displayed 
reduced ability to block corticotroph cell proliferation in 
response to dexamethasone stimulation, supporting a role 
for CABLES1 as a regulator of the corticotroph cell growth. 
Ours is the first study to identify a human phenotype 
associated with CABLES1 germline mutations.
The CABLES1 protein was originally described as an 
interacting partner and substrate of the cyclin-dependent 
kinase-3 (CDK3) (Matsuoka  et  al. 2000, Yamochi  et  al. 
2001). It plays an important role in neural development 
during embryogenesis, as inferred from in vitro studies and 
from the mouse and zebrafish models of gene inactivation 
(Zukerberg et al. 2000, Groeneweg et al. 2011, Mizuno et al. 
2014). CABLES1 is highly expressed in the nucleus of 
proliferating cells, where it is tightly regulated throughout 
the cell cycle, peaking at mid-late G1 (Matsuoka  et  al. 
2000, Wu et al. 2001, Yamochi et al. 2001). In addition to 
CDK3, CABLES1 is a substrate for other protein kinases, 
including CDK2, 14-3-3, AKT, CDK5 and ABL, also serving 
as an adaptor protein for the last two (Zukerberg  et  al. 
2000, Wu et al. 2001, Shi et al. 2015b). Another important 
function of this protein is to stabilize regulators of the 
cell cycle, such as CDKN1A (P21), CDK5R1 (P35) and 
TP63, preventing their degradation (Zukerberg et al. 2000, 
Wang et al. 2010b, Groeneweg et al. 2011, Shi et al. 2015a). 
CABLES1 also interacts with TP53 and TP73, triggering 
apoptosis (Tsuji et al. 2002).
The CABLES1 protein is widely expressed among 
tissues and is lost in a variety of human cancers 
(endometrial, ovarian, colorectal, lung and squamous 
cell carcinomas) (Kirley  et  al. 2005a). CABLES1 gene 
inactivation promotes cell proliferation and survival, as 
well as tumor formation in vitro and replicates the human 
neoplasms in mouse models (Wu et al. 2001, Dong et al. 
2003, Zukerberg  et  al. 2004, Kirley  et  al. 2005a,b). The 
tumor suppressor activity of CABLES1 is inhibited by 
14-3-3 or AKT-mediated phosphorylation (Shi et al. 2015b).
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Figure 2
ACTH, CABLES1 and CDKN1B expression in corticotropinomas. We compared ACTH, CABLES1 and CDKN1B immunostaining in samples from the four 
patients with putative CABLES1 mutations with samples from two patients negative for such alterations (one representative example is presented).  
ACTH immunostaining was observed in the vast majority of the cells in all the cases, except for Patient 1, for whom only 50% of the cells were 
immunoreactive (immunoreactivity for other pituitary hormones was ruled out). All the samples displayed positive CABLES1 cytoplasmic and, 
predominantly, nuclear immunoreactivity. In specimens that contained areas of non-tumoral pituitary, reduced CABLES1 staining was observed in the 
corticotropinomas, compared with the surrounding tissue (Supplementary Fig. 1), in concordance with previous data (Roussel-Gervais et al. 2016). 
Nevertheless, we did not observe differences in the CABLES1 immunostaining between samples with and without putative CABLES1 mutations. In contrast, 
while in controls CDKN1B staining was moderately intense in the cytoplasm of the great majority of the cells and in the nucleus of 50–60% of them, only 
weak cytoplasmic staining and very few cells with nuclear staining were observed in the cases with putative CABLES1 mutations (<10% cells with nuclear 
staining for Patients 1 and 2 and 30–40% cells with weak nuclear staining for Patients 3 and 4). Magnification in all the images: 10×, inserts: 20×.
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Interestingly, CABLES1 could provide a link 
between two important molecular mechanisms 
disrupted in corticotropinomas: dysfunction of the 
CDK/cyclin-dependent cell cycle regulation and 
activation of the epidermal growth factor receptor 
(EGFR) pathway (Fukuoka et al. 2011, Liu et al. 2011a,b). 
The RAC-alpha serine/threonine-protein kinase (AKT1), 
one of the main effectors of EGFR, can inactivate CABLES1 
by phosphorylation, neutralizing this way the regulatory 
effect of CABLES1 over the CDK/cyclin complexes 
(Fukuoka et al. 2011, Shi et al. 2015b).
Although a characteristic phenotype cannot be 
inferred from such a small number of patients, we found 
some noteworthy features. The four patients had young-
onset macroadenomas, in agreement with previous 
observations suggesting that germline mutations in 
pituitary adenoma-causative genes are relatively frequent 
among patients with such characteristics (Stratakis et al. 
2010, Tichomirowa et al. 2011). The tumors in the two 
adults were particularly large and aggressive, suggesting 
that, perhaps, they had arisen years before their 
diagnoses.
Figure 3
CABLES1 mutant proteins have lost their growth 
inhibition activity. (A) Schematic representation 
of tamoxifen-inducible chimeric CABLES1 proteins 
fused to the ERtam ligand-binding domain. Upon 
stable transduction of AtT-20 cells, wild-type (WT) 
and mutant ERtam-CABLES1 proteins are expressed 
at similar levels as revealed by Western blot 
against the Flag epitope. (B) Growth curves of 
AtT20/D16v-F2 cells expressing WT ERtam-CABLES1 
treated with vehicle (ethanol), tamoxifen, 
dexamethasone or both, as indicated. All the 
conditions rendered statistically significant 
differences in cell counts at all time points. 
To analyze exclusively the effect of CABLES1 on 
cell growth, only the tamoxifen treatment was 
used for experiments with the mutant proteins. 
(C, D, E and F) Growth curves for AtT20/D16v-F2 
cells expressing CABLES1 p.E178K (C), p.L240F (D), 
p.G312D (E) or p.D463G (F) mutant protein in 
vehicle and tamoxifen-treated cells. There were 
no statistically significant differences in cell count 
at the different time points, meaning that  
these variants have lost the ability to suppress  
cell growth.
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Considering that our patients had sporadic disease 
presentation, and given that corticotropinomas rarely 
remain asymptomatic over time, we could assume an 
incomplete penetrance for CABLES1-associated CD, which 
could explain the low frequency of these cases. Along 
these lines, it is important to emphasize that incomplete 
penetrance is a frequent finding among kindreds with 
pituitary adenoma-associated germline alterations 
(Williams  et  al. 2014, Iacovazzo  et  al. 2017). The study 
of large pedigrees with multiple cases of CD might be 
necessary to identify additional cases. However, the finding 
of multiple patients with CD in the same family is quite 
an infrequent phenotype: only 7.9% of the AIP mutation-
negative FIPA families include CD, and only 1.4% of 
the families are ‘homogeneous’ for corticotropinomas 
(Hernández-Ramírez et al. 2015). On the other hand, as we 
could not establish the pattern of inheritance in three of 
the cases, de novo mutations cannot be confirmed or ruled 
out. A caveat of our study is that we could not rule out 
that the CABLES1 mutations found in the adult patients 
were somatic defects, as germline DNA samples were not 
available from these cases. It is however noteworthy that 
the father of Patient 3 carries the CABLES1 mutation: this 
may suggest that CABLES1 mutations may predispose to 
CD and potentially be associated with very rare cases of 
familial CD, with incomplete penetrance.
Another interesting feature is the absence of somatic 
USP8 mutations in our patients. This is the most common 
genetic defect so far identified in corticotropinomas, 
being found in around 40% of the tumors (Pérez-
Rivas  et al. 2015, Reincke  et al. 2015). We have recently 
identified such mutations in one-third of our pediatric CD 
patients (Faucz  et al. 2017). The absence of this somatic 
defect somehow mirrors the absence of GNAS1 mutations 
in patients with somatotropinomas due to AIP mutations, 
suggesting that the genetic defects causing tumors due 
to germline predisposition are different than those 
found in non-inherited pituitary adenomas (Hernández-
Ramírez et al. 2015).
The histopathological analysis of the samples 
revealed other common features among the four cases. 
CABLES1 expression ranged from low to moderate, but it 
was not completely absent in any of the tumors and was 
predominantly nuclear. However, the nuclear CDKN1B 
(P27) staining was particularly affected, compared with 
other corticotropinomas. Human germline CDKN1B 
mutations are associated with approximately 2% of the 
cases of MEN1 mutation-negative multiple endocrine 
neoplasia (Georgitsi  et  al. 2007). Cases associated with 
CDKN1B mutations display a heterogeneous phenotype, 
referred to as MEN4, encompassing parathyroid and 
pituitary adenomas, neuroendocrine tumors and various 
benign and malignant tumors (Pellegata  et  al. 2006). 
Pituitary tumors have been reported in nine MEN4 
patients so far, only one of them with CD (Agarwal et al. 
2009, Lee & Pellegata 2013, Sambugaro  et  al. 2015). 
However, Cdkn1b-knockout (KO) mice develop, among 
other phenotypic abnormalities, ACTH-secreting 
hyperplasia or adenomas of the pituitary pars intermedia 
with full penetrance (Fero  et  al. 1996, Kiyokawa  et  al. 
1996, Nakayama et al. 1996).
More importantly, nuclear CDKN1B immuno-
staining is significantly reduced in pituitary adenomas 
of all types, particularly in corticotropinomas, in 
association with high Ki-67 expression, and is lost in 
pituitary carcinomas (Lidhar et al. 1999, Korbonits et al. 
2002). This low expression is very likely not due to 
mutations or deletions, since these alterations have 
not been detected at the somatic level, but caused by 
posttranslational events (Dahia  et  al. 1998). The best-
characterized mechanism for this in CD is increased 
CDKN1B phosphorylation by cyclin E (upregulated 
in corticotropinomas), which inactivates the protein 
and triggers its degradation, although 14-3-3 and 
AKT-mediated phosphorylation have the same effect 
(Korbonits  et  al. 2002, Susaki & Nakayama 2007, 
Roussel-Gervais et al. 2010). We observed that CDKN1B 
nuclear expression was particularly low in tumors with 
putative CABLES1 mutations. As CABLES1 is known to 
stabilize and prevent the degradation of other cyclin-
dependent kinases, we could speculate that our findings 
are due to increased CDKN1B degradation as a result of 
impaired CABLES1 function. This is in agreement with 
the rough correlation between CABLES1 and CDKN1B, 
but not cyclin E expression by immunohistochemistry 
in CD patients (Roussel-Gervais  et  al. 2016). Further 
experiments are required to confirm this mechanism, 
although they are beyond the scope of the present article.
We acknowledge the limitations of our study. Given 
that our centers are tertiary referral hospitals, aggressive 
or atypical cases of CD might be overrepresented in our 
cohorts. Although only a minority of the patients had 
macroadenomas, the frequency was higher than what 
is reported in the literature (Storr et al. 2011). The adult 
CD cohort included only patients for whom tissue was 
available, which means macroadenomas would be 
overrepresented. While these selection biases might 
preclude any inference on the prevalence of CABLES1 
variants in the general population of patients with CD, it 
was probably the uniqueness of our cases, which allowed 
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us to identify such uncommon genetic alterations. Also, 
we do not have a firm basis to explain why the loss of 
function of a ‘generic’ tumor suppressor such as CABLES1 
caused a pituitary-specific phenotype in our patients. We 
could speculate that the missense variants found in these 
cases might cause loss of crucial pituitary-specific protein–
protein interactions, but further studies are required to 
better characterize the function of this tumor suppressor 
in the corticotroph cells.
Our results provide evidence for a role of CABLES1 
as a novel pituitary tumor suppressor. The function of 
the CABLES1 protein as a regulator of different elements 
of the molecular pathways that control the cell cycle 
progression and apoptosis links genes previously known 
to have a role in the pathogenesis of CD. A more 
detailed characterization of such regulatory networks 
will allow a better understanding of the genetic basis of 
corticotropinomas, providing grounds for the search of 
novel therapeutic targets.
Conclusions
We have identified four potentially pathogenic missense 
CABLES1 variants as a novel, although infrequent, cause 
of CD in children and young adults. The CABLES1 protein 
functions as a glucocorticoid-responsive regulator of the 
effect of growth factor receptor activation on cell cycle 
control in the corticotroph cells. The putative CABLES1 
mutations found in our patients impair the ability of 
this tumor suppressor to control cell proliferation and 
might influence the function of CDKN1B by regulating 
its subcellular localization and/or degradation. Further 
studies are required to characterize in detail the function 
of this tumor suppressor in the corticotroph cells.
Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/
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